How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves’ disease
Endocrine Journal · 2025
DOI: 10.1507/endocrj.ej25-0204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2025. Verfasst von Tsukasa Murakami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Noguchi Thyroid Clinic and Hospital Foundation, Beppu 874-0902, Japan. Hauptthemen laut MEDLINE: Methimazole, Graves Disease, Potassium Iodide, Antithyroid Agents. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Noguchi Thyroid Clinic and Hospital Foundation, Beppu 874-0902, Japan.
Zitieren
APA
Murakami, T., Higaki, N., Nishijima, Y., Tani, J., & Noguchi, H. (2025). How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves’ disease. Endocrine Journal. https://doi.org/10.1507/endocrj.ej25-0204
Vancouver
Murakami T, Higaki N, Nishijima Y, Tani J, Noguchi H. How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves’ disease. Endocrine Journal. 2025. doi:10.1507/endocrj.ej25-0204
BibTeX
@article{Murakami2025,
author = {Murakami, Tsukasa and Higaki, Naoyuki and Nishijima, Yui and Tani, Junichi and Noguchi, Hitoshi},
title = {How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves’ disease},
journal = {Endocrine Journal},
year = {2025},
doi = {10.1507/endocrj.ej25-0204}
}
EUVIMED